Clinical Trial Update: Isatuximab in Lung Transplant Recipients [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 trial of isatuximab for antibody-mediated rejection in lung transplant recipients was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allosensitization
• Lung Transplant Rejection

Drugs mentioned

• SARCLISA (isatuximab)

Snippet

Sponsor: NYU Langone Health | Conditions: Antibody-mediated Rejection, Allosensitization | EARLY_Phase 1 | Status: WITHDRAWN